Previous 10 | Next 10 |
SAN FRANCISCO and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today ...
These Biotech Stocks Are Trending In The Stock Market Now As an investor in the stock market , biotech stocks have always been an intriguing sector to invest in. Companies in this industry are usually less affected by global events and economic uncertainties. This is because, re...
Shares of Kinnate Biopharma (KNTE) are up 13% as the company announced the FDA has cleared its IND application for its lead candidate, KIN-2787, a RAF inhibitor for solid tumors.The company plans to begin a phase 1 trial mid-year.KIN-2787 is specifically designed to target Class II ...
Kinnate Biopharma (KNTE): Q1 GAAP EPS of -$0.40 misses by $0.01.As of March 31, 2021, the total of cash and cash equivalents and investments was $383.1 million.Press release. For further details see: Kinnate Biopharma EPS misses by $0.01
KIN-2787 is the company’s RAF inhibitor candidate for patients with mutant BRAF-driven solid tumors Planned initiation of Phase 1 clinical trial for KIN-2787 in mid-2021 Ended the quarter with cash and cash equivalents and investments of $383.1 million Clo...
Financing led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital The joint venture will have exclusive license to develop and commercialize Kinnate’s currently most advanced kinase inhibitor candidates in Greater China ...
Data highlights pre-clinical activity of KIN-2787 in Class II and Class III BRAF-mutant models Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for diffic...
SAN FRANCISCO and SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, toda...
Kinnate Biopharma (KNTE): FY GAAP EPS of -$5.28.Cash and cash equivalents and short-term investments of $396.9M.Press Release For further details see: Kinnate Biopharma reports FY results
Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers Progress towards IND filing for KIN-2787, our RAF inhibitor candidate, in the first half of 2021 and initiating a Phase 1 clinical trial later in the year...
News, Short Squeeze, Breakout and More Instantly...
Kinnate Biopharma Inc. Company Name:
KNTE Stock Symbol:
NASDAQ Market:
Kinnate Biopharma Inc. Website:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced th...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...